| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials
|
Amiri-Kordestani, L.
|
|
|
31 |
12 |
p. 1704-1708
|
artikel
|
| 2 |
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
|
Popat, S.
|
|
|
31 |
12 |
p. 1734-1745
|
artikel
|
| 3 |
Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19
|
O'Callaghan, M.E.
|
|
|
31 |
12 |
p. 1780-1782
|
artikel
|
| 4 |
Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?
|
van de Garde, E.M.W.
|
|
|
31 |
12 |
p. 1779-1780
|
artikel
|
| 5 |
Bone health in cancer: ESMO Clinical Practice Guidelines †
|
Coleman, R.
|
|
|
31 |
12 |
p. 1650-1663
|
artikel
|
| 6 |
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis
|
Özdemir, B.C.
|
|
|
31 |
12 |
p. 1775-1778
|
artikel
|
| 7 |
Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
|
Tan, L.
|
|
|
31 |
12 |
p. 1599-1600
|
artikel
|
| 8 |
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
|
Bandini, M.
|
|
|
31 |
12 |
p. 1755-1763
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
31 |
12 |
p. iv
|
artikel
|
| 10 |
ESMO localised colon cancer guidelines: ‘can we improve on our surveillance protocols?’
|
Jain, A.
|
|
|
31 |
12 |
p. 1778-1779
|
artikel
|
| 11 |
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|
Miller, R.E.
|
|
|
31 |
12 |
p. 1606-1622
|
artikel
|
| 12 |
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
|
Lambertini, M.
|
|
|
31 |
12 |
p. 1664-1678
|
artikel
|
| 13 |
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
|
Marinelli, D.
|
|
|
31 |
12 |
p. 1746-1754
|
artikel
|
| 14 |
Last but not least: antibody–drug conjugates in hormone receptor-positive metastatic breast cancer
|
Stecklein, S.R.
|
|
|
31 |
12 |
p. 1594-1596
|
artikel
|
| 15 |
Leveraging existing data to contextualize phase II clinical trial findings in oncology
|
Ray, E.M.
|
|
|
31 |
12 |
p. 1591-1593
|
artikel
|
| 16 |
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
|
Lin, J.J.
|
|
|
31 |
12 |
p. 1725-1733
|
artikel
|
| 17 |
New hints towards a precision medicine strategy for IDH wild-type glioblastoma
|
White, K.
|
|
|
31 |
12 |
p. 1679-1692
|
artikel
|
| 18 |
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
|
Laskin, J.
|
|
|
31 |
12 |
p. 1693-1703
|
artikel
|
| 19 |
Patient selection biomarker strategies for PARP inhibitor therapy
|
Pilié, P.G.
|
|
|
31 |
12 |
p. 1603-1605
|
artikel
|
| 20 |
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study
|
Giannatempo, P.
|
|
|
31 |
12 |
p. 1764-1772
|
artikel
|
| 21 |
Positioning checkpoint blockade in urothelial cancer: PURE-01 and PEANUTS
|
Linch, M.
|
|
|
31 |
12 |
p. 1601-1602
|
artikel
|
| 22 |
Pulmonary toxicity in patients treated with immune checkpoint inhibitors and radiation
|
Senan, S.
|
|
|
31 |
12 |
p. 1597-1598
|
artikel
|
| 23 |
Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer
|
Heudel, P.
|
|
|
31 |
12 |
p. 1773-1775
|
artikel
|
| 24 |
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
|
Kalinsky, K.
|
|
|
31 |
12 |
p. 1709-1718
|
artikel
|
| 25 |
Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors
|
Shaverdian, N.
|
|
|
31 |
12 |
p. 1719-1724
|
artikel
|
| 26 |
Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients
|
Mir, O.
|
|
|
31 |
12 |
p. 1782-1784
|
artikel
|
| 27 |
Table of Contents
|
|
|
|
31 |
12 |
p. i-ii
|
artikel
|
| 28 |
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|
Cardoso, F.
|
|
|
31 |
12 |
p. 1623-1649
|
artikel
|
Tijdschrift beschrijving